Depressive Disorder News and Research

RSS

Older adults with depression do not respond to emotional stimuli, says study

Scientists have found an important clue in the quest to understand why people who suffer from depression in later life are harder to treat and keep well in the long term.

5 May 2010

Mood and anxiety disorders associated with poor health outcomes

Rates of mood and anxiety disorders appear to decline with age but the conditions remain common in older adults, especially women, according to a report in the May issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.

20 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Worsening suicidality thoughts while on antidepressants linked to specific changes in brain function

While antidepressant medications have proven to be beneficial in helping people overcome major depression, it has long been known that a small subset of individuals taking these drugs can actually experience a worsening of mood, and even thoughts of suicide. No clinical test currently exists to make this determination, and only time - usually weeks - can tell before a psychiatrist knows whether a patient is getting better or worse.

12 Apr 2010

Scientists discover and block pathway responsible for link between stress, anxiety and depression

Scientists at The University of Western Ontario have discovered the biological link between stress, anxiety and depression. By identifying the connecting mechanism in the brain, this high impact research led by Stephen Ferguson of Robarts Research Institute shows exactly how stress and anxiety could lead to depression.

12 Apr 2010

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

8 Apr 2010

PMDD often misdiagnosed as major depression or other mood disorder

As science slowly, but continually, unravels the causes of disorders, it increasingly teases apart biological threads that, when spooled together, begin to take on the warp and weft of separate disorders.

31 Mar 2010

Clinical Data completes NDA submission for vilazodone

Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.

23 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Broad application of bipolar diagnosis in children may do more harm than good

Troubled children diagnosed with bipolar disorder may fare better with a different diagnosis, according to researchers at The Hastings Center.

18 Mar 2010

Moderating treatment response in depression: Role of personality factors

A study published in the current issue of Psychotherapy and Psychosomatics addresses the role of personality factors in moderating treatment response in depression.

8 Mar 2010

Study: Offspring of two parents with schizophrenia more likely to develop same illness

Offspring of two parents with schizophrenia or bipolar disorder appear more likely to develop the same illness or another psychiatric condition than those with only one parent with psychiatric illness, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Mar 2010

Association between depression and obesity bidirectional

Obesity appears to be associated with an increased risk of depression, and depression also appears associated with an increased risk of developing obesity, according to a meta-analysis of previously published studies in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Mar 2010

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

The next advance in treating major depression may relate to a group of brain chemicals that are involved in virtually all our brain activity, according to a study published today in Biological Psychiatry.